The content on this site is intended for healthcare professionals only
At a press conference during the 2013 AACR Annual Meeting, Dr Darrin Stuart discussed vemurafenib-resistant tumours in patients with melanoma that showed reduced growth after cessation of treatment and drug resistance was prevented by intermittent treatment, and in animal models.
BRAF mutations are found in more than half of all cases of melanoma, and previous studies have shown vemurafenib increases survival for these patients, according to Stuart. However, most patients relapse with lethal, drug-resistant disease.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
Choosing the right patients for transplant
ESMO 2024: Latest in EGFR mutated NSCLC
Addressing the rise of multiple myeloma in Rwanda
